Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of America Securities maintained a Hold rating on the stock and has a $32.60 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Li has given his Hold rating due to a combination of factors including Zai Lab’s recent financial performance and future projections. The company reported a slight decrease in quarterly revenue, although it still showed year-over-year growth. This mixed financial outcome, alongside increased research and development expenses due to upfront payments, suggests a cautious outlook.
Moreover, while Zai Lab’s gross profit margin has improved, the net loss forecast has been adjusted upwards, indicating potential challenges ahead. The company’s pipeline development is progressing, with new products entering clinical trials, which provides some optimism. However, the slowdown in growth of core products tempers this positive outlook, leading to a balanced Hold rating.
According to TipRanks, Li is ranked #7496 out of 9472 analysts.